Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
GSK159797 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| GSK159797 (10, 15, and 20mcg) | EXPERIMENTAL | GSK159797 (10, 15, and 20mcg) |
| salbutamol | EXPERIMENTAL | salbutamol |
| salmeterol 50mcg | EXPERIMENTAL | salmeterol 50mcg |
| placebo | PLACEBO_COMPARATOR | placebo |
| Name | Type | Description |
|---|---|---|
| GSK159797 (10, 15, and 20mcg) | DRUG | GSK159797 (10, 15, and 20mcg) |
| salbutamol | DRUG | salbutamol |
| salmeterol 50mcg | DRUG | salmeterol 50mcg |
| placebo | DRUG | placebo |
| GSK159797 | DRUG | - |
Inclusion criteria: * Subjects with documented history of persistent asthma using corticosteroids at a total daily dose of 200 to 200mcg of FP or equivalent corticosteroid * Female subjects only using acceptable birth control method * Non-smokers * FEV1 between 60 and 90% predicted * Increase in FE...
GSK159797 is an investigational small molecule being studied for the treatment of chronic obstructive pulmonary disease (COPD). It is in Phase 2 clinical development and has been evaluated in patients with mild to moderate asthma as well, though its primary focus is on respiratory conditions.
GSK159797 is being developed by GSK plc, a global biopharma company listed on the London Stock Exchange under the ticker GSK. The company is conducting clinical trials to assess the drug's safety and efficacy in respiratory diseases.
GSK159797 is in Phase 2 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. Two Phase 2 trials have been completed to evaluate its effects in patients with respiratory conditions.
GSK159797 has been studied in two completed Phase 2 clinical trials. NCT00354666 investigated single doses in patients with mild to moderate asthma, and NCT00358488 examined repeat doses in asthmatic patients. Both trials were randomized, double-blind, and placebo-controlled, with a combined enrollment of 74 participants.
GSK159797 is a distinct investigational compound with no alternative names listed. It is being developed specifically for respiratory indications and is not known to be identical to any other marketed or investigational drug.